Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
BI-1808 combined with pembrolizumab elicited a 24% confirmed overall response rate in heavily pretreated, platinum-resistant recurrent ovarian cancer.
PD-L1 IHC 22C3 pharmDx gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Neoadjuvant Ivonescimab Plus Chemotherapy Yields pCRs in Resectable HNSCC
2
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
3
Dr Fonseca on Treatment Selection at First Relapse in Multiple Myeloma
4
Pooled Analysis Reveals Strong Pirtobrutinib Efficacy in Frontline CLL
5